NO20053783L - Behandling av godartet prostatahyperplasi - Google Patents

Behandling av godartet prostatahyperplasi

Info

Publication number
NO20053783L
NO20053783L NO20053783A NO20053783A NO20053783L NO 20053783 L NO20053783 L NO 20053783L NO 20053783 A NO20053783 A NO 20053783A NO 20053783 A NO20053783 A NO 20053783A NO 20053783 L NO20053783 L NO 20053783L
Authority
NO
Norway
Prior art keywords
benign prostatic
prostatic hyperplasia
treatment
lonidamine
prophylaxis
Prior art date
Application number
NO20053783A
Other languages
English (en)
Other versions
NO20053783D0 (no
Inventor
George Tidmarsh
Original Assignee
Treshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treshold Pharmaceuticals Inc filed Critical Treshold Pharmaceuticals Inc
Publication of NO20053783D0 publication Critical patent/NO20053783D0/no
Publication of NO20053783L publication Critical patent/NO20053783L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Det beskrives en fremgangsmåte for terapi eller profylakse av benign prostatisk hyperplasi ved administrering av lonidamin eller en lonidaminanalog. Videre tilveiebringes det enhetsdoseringsformer av lonidamin eller en analog, brukbar for slik terapi eller profylakse.
NO20053783A 2003-01-17 2005-08-09 Behandling av godartet prostatahyperplasi NO20053783L (no)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US44111003P 2003-01-17 2003-01-17
US44234403P 2003-01-23 2003-01-23
US45866503P 2003-03-28 2003-03-28
US45884603P 2003-03-28 2003-03-28
US45866303P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US47290703P 2003-05-22 2003-05-22
US48826503P 2003-07-18 2003-07-18
US49616303P 2003-08-18 2003-08-18
PCT/US2004/001141 WO2004064735A2 (en) 2003-01-17 2004-01-16 Treatment of benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
NO20053783D0 NO20053783D0 (no) 2005-08-09
NO20053783L true NO20053783L (no) 2005-09-27

Family

ID=32777423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053783A NO20053783L (no) 2003-01-17 2005-08-09 Behandling av godartet prostatahyperplasi

Country Status (13)

Country Link
US (4) US6989400B2 (no)
EP (2) EP1610778A4 (no)
JP (2) JP2006518343A (no)
KR (2) KR20050098249A (no)
AU (2) AU2004206870A1 (no)
BR (1) BRPI0406796A (no)
CA (2) CA2513575A1 (no)
DE (1) DE04702967T1 (no)
ES (1) ES2254046T1 (no)
IL (1) IL169685A0 (no)
MX (2) MXPA05007572A (no)
NO (1) NO20053783L (no)
WO (2) WO2004064735A2 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US7524885B2 (en) * 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
JP2006518343A (ja) 2003-01-17 2006-08-10 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド エネルギー減損因子を用いた良性前立腺増殖症の処置
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
MX2008010833A (es) * 2006-02-24 2008-11-12 Univ Texas Compuestos de hexosa para tratar cancer.
US7855225B2 (en) 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
CA2694216A1 (en) 2007-07-24 2009-01-29 Astellas Pharma Inc. Benzimidazole derivative
AU2008292420A1 (en) 2007-08-31 2009-03-05 Astellas Pharma Inc. Piperidine derivative
US8603123B2 (en) * 2008-04-28 2013-12-10 Urotech, Inc. Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration
DK2331092T3 (da) 2008-08-21 2014-05-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
NZ594434A (en) * 2009-01-29 2014-11-28 Young Hee Ko Compositions and methods for the treatment of cancer
WO2013153821A1 (ja) * 2012-04-12 2013-10-17 Omura Satoshi Ｐｄｋ４阻害剤及びその利用
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
WO2015108933A1 (en) 2014-01-14 2015-07-23 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
WO2022061008A2 (en) * 2020-09-17 2022-03-24 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
DE69531558T2 (de) 1995-06-07 2004-03-18 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
FR2737721B1 (fr) * 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
DE69521525T2 (de) 1995-10-18 2002-04-25 Kanoldt Arzneimittel Gmbh Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
DE19621319A1 (de) 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IT1289939B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用
AU3980499A (en) * 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6001865A (en) * 1999-05-04 1999-12-14 Angelini Pharmaceuticals Inc. 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents
JP2006518343A (ja) 2003-01-17 2006-08-10 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド エネルギー減損因子を用いた良性前立腺増殖症の処置
MXPA06010938A (es) * 2004-03-25 2007-01-25 Univ Michigan Co-cristales de gossipol y el uso de los mismos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Also Published As

Publication number Publication date
MXPA05007571A (es) 2005-11-17
DE04702967T1 (de) 2006-06-22
WO2004064736A3 (en) 2005-05-06
WO2004064735A2 (en) 2004-08-05
EP1592430A4 (en) 2006-05-31
KR20050098249A (ko) 2005-10-11
AU2004206870A1 (en) 2004-08-05
EP1610778A4 (en) 2006-05-31
WO2004064735A3 (en) 2004-12-16
EP1610778A2 (en) 2006-01-04
US20050271723A1 (en) 2005-12-08
US20040167196A1 (en) 2004-08-26
IL169685A0 (en) 2007-07-04
JP2006516571A (ja) 2006-07-06
NO20053783D0 (no) 2005-08-09
KR20050098250A (ko) 2005-10-11
CA2513572A1 (en) 2004-08-05
BRPI0406796A (pt) 2006-01-17
US6989400B2 (en) 2006-01-24
WO2004064736A2 (en) 2004-08-05
AU2004206869A1 (en) 2004-08-05
JP2006518343A (ja) 2006-08-10
US20050272796A1 (en) 2005-12-08
EP1592430A2 (en) 2005-11-09
ES2254046T1 (es) 2006-06-16
CA2513575A1 (en) 2004-08-05
MXPA05007572A (es) 2005-11-17
US20050272795A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
NO20053783L (no) Behandling av godartet prostatahyperplasi
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
NO20051692L (no) Anvendelse av indolylderivater for fremstilling av et medikament for behandling av allergisk rhinitt
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
EA200401043A1 (ru) Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm )
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
AU2002360592A8 (en) Inhibitors of hepatitis c virus
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
HUP0000558A2 (hu) Aktív D-vitamin analógok alkalmazása prosztatabetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
NO20076616L (no) 17beta-HSD1- og STS-inhibitorer
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
CY1106319T1 (el) Τοπικη θepαπεια στη μασταλγια
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
NO951498L (no) Farmasöytisk preparat for behandling av osteoporose
NO20051168L (no) Anvendelse av fermentert hvetekimekstrakt som anti-inflammasjonsmiddel
BRPI0606833A2 (pt) uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser